|
|
|
Wednesday, August 27, 2008
 Latest
Alzheimers Medical and Health News Headlines
|
|
Alzheimers Medical and Health News Headlines
|
|
|
|
|
|
|
|
|
|
|
All Recent Alzheimers Medical Condition News Headlines |
|
|
|
|
|
|
Alzheimer's vs. dementia? subtle difference
Reagan Jr. on Thatcher daughter's memory loss tell-all: "monumental bad taste." (Source: ABC News: Health)...
POSTED 08/26/2008 at 09:24 AM --
|
Palliative care must be a priority for dementia
Alzheimer Scotland welcomes the attention drawn to 'inconsistencies' in palliative care for different conditions in the recent Review of palliative care services in Scotland report from Audit Scotland. This report has prompted a pledge from the Scottish Government for a national plan to improve palliative care provision. (Source: Health News from Medical News Today)...
POSTED 08/26/2008 at 05:00 AM --
|
Advances in conceptualizing disease progression in alzheimer's disease
A hallmark of this year's ICAD meeting was the wealth of new clinical trials information in Alzheimer's Disease (AD). Years of basic and preclinical research have paved the road for development of new medications and biologics. Results from many new clinical trials were provided, ranging from promising Phase I and II trials to some disappointing Phase II and III results. (Source: Health News from Medical News Today)...
POSTED 08/26/2008 at 04:00 AM --
|
Early-stage alzheimer's patients 'don't want to be stigmatized'
Being treated with dignity is a universal human need, and perhaps even more so if you have early Alzheimer's disease, a new report ... (Source: USATODAY.com Health)...
POSTED 08/25/2008 at 10:37 PM --
|
Uncertainties prevail over human health benefits of polyphenols
Despite scores of studies documenting the effects of healthful plant nutrients called polyphenols in protecting nerves from damage, it would be "unwise" to assume that the same protective effects occur for Alzheimer's disease (AD) and other human disorders, a new report concludes. (Source: ScienceDaily Headlines)...
POSTED 08/25/2008 at 01:59 AM --
|
Role of pramipexole in key research areas of parkinsons disease management discussed at 12th efns congress
Madrid, Spain, 25 August 2008 Data presented during the 12th Congress of the European Federation of Neurological Sciences (EFNS), held in Madrid, Spain, from 23 to 26 August, highlight important new ongoing studies with pramipexole in a number of key research areas in Parkinsons disease (PD): clinical benefits of early treatment initiation, management of PD-related depressive symptoms and a new formulation currently under investigation.
Professor Anthony Schapira, Chairman of the University Department of Clinical Neurosciences, Institute of Neurology, Queen Square, UCL, and Professor of Neurology at the National Hospital and Royal Free Hospital, London, UK and lead study investigator for PROUD*,1, presented a new approach to investigate the slowing of clinical progression in PD, a key focus of current research due to this important unmet need. Previous pramipexole studies have suggested a potential neuroprotective effect, such as the CALM-PD** study2,3 and in vitro studies. PROUD, however, is the first study to combine measurements of clinical outcomes in a PD patient with measurements of dopamine transporter density of certain brain areas (basal ganglia), through a SPECT imaging arm of the study.1
Commenting on the study so far, Professor Schapira said: The debate on when and how to treat early Parkinsons disease patients has been ongoing. Currently, treatment would typically be initiated when symptoms have caused disability. However, providing the medical evidence for a treatment to retard or prevent the progression of PD is a major therapeutic priority and the PROUD study aims to shed more light into this question. Pramipexole was considered an optimal candidate for this study due to evidence suggesting possible benefits to PD patients beyond treating the well-known core symptoms. Based on the unique technique used in this study, PROUD may provide a major breakthrough in our understanding of early PD treatment which would offer hope to the ever increasing number of patients diagnosed with Parkinsons disease.
Study results are expected to be available in 2009.
Pramipexole studies pursuing other new avenues of research to meet treatment needs
Further areas of current PD research with pramipexole are the management of PD-related depressive symptoms and ongoing studies to evaluate a new formulation so as to provide physicians and patients using pramipexole with an even broader treatment regimen to better meet differing patient needs and lifestyles.4,5,6
PD-related depressive symptoms
A new pramipexole study conducted in approximately 70 European centres aims to assess management of depressive symptoms in PD patients.7 Emerging data suggest that pramipexole may have a positive effect on depressive symptoms and motivation associated with PD, in addition to effectively controlling the motor symptoms of PD.8-16 The specific receptor profile of pramipexole may be responsible for the possible antidepressant properties of this compound and clinical research is ongoing to determine this aspect of pramipexoles pharmacological profile in more detail.17,18,19
Professor Paolo Barone, Department of Neurological Sciences, University of Napoli-Federico II, Naples, Italy and lead investigator of both PRODEST4 and the new European study7 said: Previously, the PRODEST study identified that PD-related depressive symptoms are common, with nearly half of those PD patients receiving anti-depressants continuing to experience depressive symptoms. These symptoms impact significantly on quality of life, both for PD patients and their carers. The new European study aims to provide answers on the role pramipexole may play in managing these commonly experienced PD-related depressive symptoms that are often under-recognised and consequently under-treated.
Widening choice of pramipexole treatment options
Favourable results of pharmacokinetic phase I studies with a new once daily pramipexole extended release formulation were presented at EFNS and support the development of this new formulation.5,6 Pramipexole is the leading dopamine agonist treatment for PD and these ongoing studies aim to add to the existing treatment regimen with a once daily formulation to go one step further to meeting a broader range of patients needs.
Please be advised
This release is provided by Boehringer Ingelheim Corporate Headquarters in Germany. Please be aware that there may be national differences between countries regarding specific medical information, including licensed uses. Please take account of this when referring to the information provided in this document. This information is not intended for distribution within the U.S.A.
Notes to Editor:
About Parkinsons disease (PD)
PD is the second most common chronic neurological disorder in older adults after Alzheimer`s. Its worldwide prevalence is estimated to be approximately one to two percent of those over 65 years.20,21 Although traditionally PD is associated with motor symptoms (such as tremor, rigidity, slowed motion, imbalance, shuffling gait, loss of facial expression), the non-motor symptoms, including depressive symptoms, pain, cognitive impairment and sleep disorders can be significant. The symptoms can vary from patient to patient, but worsen over time.
About PROUD1 (*Assessment of Potential ImPact of PRamipexole On Underlying Disease)
The PROUD study was designed to test the hypothesis that early administration of pramipexole can modify Parkinsons disease and delay the progression of motor function deterioration in early PD patients. The PROUD study is unique in its design by including a parallel SPECT imaging arm to measure the level of neuron degeneration in the brain.
534 patients with early PD in 98 centres in ten countries were randomised to receive either 1.5mg/day pramipexole or placebo. After six to nine months all patients were given pramipexole for the remainder of the 15 months. The primary endpoint of the study is the change in UPDRS part I, II and III at 15 months compared to baseline values by a blinded rater. UPDRS part I, II and III relate to mentation, behaviour and mood (I), activities of daily living (II) and motor symptoms (III). Secondary endpoints include the change in motor, cognitive and quality of life indices and striatal dopamine transporter (DAT) density by [123I] FP-CIT SPECT in 158 patients between baseline and 15 months.
**About CALM-PD
In the earlier performed CALM-PD trial, 301 patients were randomised to double-blind therapy with pramipexole or levodopa; adjuvant therapy was allowed as rescue if necessary. After four years, initial treatment with pramipexole reduced the risk of developing dyskinesias (involuntary jerking movements, themselves very disabling) by more than 50% versus initial treatment with levodopa.22 These results played a pivotal role in recent guidelines by the American Academy of Neurology which support the advantages of starting treatment with a dopamine agonist.23 While the CALM-PD trial compared the pooled analysis (both mono and combination therapy) after two and four years, this new analysis assessed the effects of mono vs. combination therapy separately in terms of the dyskinesia rate.
About pramipexole
Pramipexole (known under the trade names Mirapexin®, Sifrol®, Mirapex® and Pexola®) is a compound from Boehringer Ingelheim research first approved in 1997 for the treatment of the signs and symptoms of idiopathic Parkinson`s disease, as monotherapy or in combination with levodopa. Pramipexole was approved in 2006 for the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome (RLS). Pramipexole is currently marketed in over 70 countries across the globe.
The most commonly reported adverse reactions in early and late Parkinsons disease in clinical trials were dizziness, nausea, dyskinesia, hypotension, somnolence, insomnia, hallucination, constipation, headache and fatigue. The most commonly reported adverse reactions in clinical trials for Restless Legs Syndrome were nausea, headache, fatigue and dizziness.
Pramipexole may cause patients to fall asleep without any warning, even while doing normal daily activities such as driving. When taking pramipexole hallucinations may occur and sometimes patients may feel dizzy, sweaty or nauseated upon standing up. It should be noted that impulse control disorders/compulsive behaviours may occur while taking medicines to treat Parkinson`s disease, including pramipexole.
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the worlds 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2007, Boehringer Ingelheim posted net sales of 10.9 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development.
References:
1 Schapira A et al. PROUD: The impact of early vs. delayed treatment with pramipexole on new onset Parkinsons disease. Poster P1366 presented at the 12th Congress of the European Federation of Neurological Sciences, Madrid, Spain, 24 August 20082 Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinsons disease progression. JAMA 2002; 287(13): 1653-16613 Jennings DL et al. InSPECT: Investigating the effect of short-term treatment with pramipexole or levodopa on [123I] and SPECT imaging. Abstract 465 at 11th International Congress of Parkinsons Disease and Movement Disorders, Istanbul 20074 Barone P et al. PRODEST Depressive symptoms in Parkinsons disease: Pattern across scales. Poster Presentation P-01 / 1.167. 10 December 2007 XVIIth WFN World Congress of Parkinsons Disease and Related Disorders5 Koenen-Bergmann, M et al. A multiple rising-dose bioequivalence Phase I study with pramipexole extended release (ER). Poster P1248 presented at the 12th Congress of the European Federation of Neurological Sciences, Madrid, Spain, 24 August 20086 Haertter, S et al. A single dose five-way cross-over study to establish an in vitro/in vivo correlation (IVIVC) for oral extended release (ER) formulations with 0.375 mg pramipexole. Poster P1244 presented at the 12th Congress of the European Federation of Neurological Sciences, Madrid, Spain, 24 August 20087 Barone P et al. Design of a randomized, placebo-controlled trial of pramipexole in patients with Parkinsons disease and depressive symptoms (study 248.596) Poster 601 presented at Movement Disorders Societys 12th International Congress of Parkinsons Disease and Movement Disorders, June 2008, Chicago, USA8 Möller JC et al. Long-term efficacy and safety of pramipexole in advanced Parkinson`s disease: results from a European multicenter trial. Mov Disord 2005 May; 20(5): 602-109 Rektorova I et al. Pramipexole and pergolide in the treatment of depression in Parkinson`s disease: a national multicentre prospective randomized study. Eur J Neurol 2003; 10(4): 399-40610 Reichmann H et al. Pramipexole in routine clinical practice. CNS Drugs 2003; 17(13): 965-97311 Lemke MR et al. Depression and Parkinsons disease. J Neurol 2004 Sep;251 Suppl 6:VI/24-7.12 Lemke MR et al. Anhedonia, depression, and motor functioning in Parkinson`s disease during treatment with pramipexole. J Neuropsychiatry Clin Neurosci 2005 Spring; 17(2): 214-20.13 Rektorova I et al. Cognitive performance in people with Parkinson`s disease and mild or moderate depression: effects of dopamine agonists in an add-on to L-dopa therapy. Eur J Neurol 2005; 12: 9-15.14 Goldberg JF et al. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004 Mar; 161(3): 564-6.15 Künig G et al. Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinsons disease. Clin Neuropharm 1999; 22: 301-305.16 Barone P et al. Pramipexole versus sertraline in the treatment of depression in Parkinsons disease: a national multicenter parallel-group randomized study. J Neurol. 2006;253(5):601-7.17 Houben J et al. Pramipexole improves depressive and motivational symptoms in Parkinsons disease. Abstract no. P575, presented at MDS 2006; Kyoto, Japan.18 Barone P et al. Depressive symptoms in Parkinsons disease: Design and methods of an observational study. Mov Disord. Vol. 21, Suppl. 15, 2006: S476.19 Barone P et al. Depression and antidepressant use in Parkinsons disease: Results from the PRODEST-PD study. Abstract P1122 poster presented at 11th Congress of EFNS, Brussels, 26 Aug 2007.20 Zhang ZX, et al. Worldwide occurrence of Parkinson`s disease: An updated review. Neuroepidemiology. 1993;12:195-208.21 de Rijk MC et al. Prevalence of Parkinsonism and Parkinsons disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinsons disease. J Neurol Neurosurg Psychiatry. 1997;62:10-5.22 Parkinson Study Group, Holloway RG et al. Pramipexole vs levodopa as initial treatment for Parkinson disease. Arch Neurol 2004; 61(7): 1044-1053.23 Miyasaki JM et al. Practice parameter: Initiation of treatment for Parkinsons disease: An evidence-based review. Neurology 2002; 58; 11-17. (Source: Boehringer Ingelheim RSS-Newsfeed)...
POSTED 08/24/2008 at 07:00 PM --
|
Lsuhsc research reports new method to protect brain cells from diseases like alzheimer's
New research led by Chu Chen, PhD, Associate Professor of Neuroscience at LSU Health Sciences Center New Orleans, provides evidence that one of the only naturally occurring fatty acids in the brain that has the ability to interact with the receptors originally identified as the targets of THC (the ps (Source: Health News from Medical News Today)...
POSTED 08/23/2008 at 04:00 AM --
|
Alzheimer's disease: compounds have potential for diagnosis, treatment
New research suggests that a select group of compounds that interact with a protein in the brain might be used in the early diagnosis and treatment of Alzheimer's disease and other dementia disorders. (Source: Health News from Medical News Today)...
POSTED 08/23/2008 at 03:00 AM --
|
Klasko takes on leadership role at byrd alzheimer’s center
Dr. Stephen Klasko was named chief executive officer of the Johnnie B. Byrd Sr. Alzheimer’s Center & Research Institute in Tampa. (Source: bizjournals.com Health Care:Hospitals headlines)...
POSTED 08/22/2008 at 01:37 PM --
|
Compounds have potential for diagnosis, treatment of alzheimer's disease
New research suggests that a select group of compounds that interact with a protein in the brain might be used in the early diagnosis and treatment of Alzheimer's disease and other dementia disorders. Scientists have discovered that these compounds interact in three specific ways with the tau protein, which is the subject of a growing body of research into the causes and progression of dementia. (Source: ScienceDaily Headlines)...
POSTED 08/22/2008 at 01:00 PM --
|
Brain stimulation improves memory in alzheimer's
NEW YORK (Reuters Health) - Electrical stimulation of the brain may improve memory and recognition in elderly people who suffer from Alzheimer's disease, results of a study hint. (Source: Reuters: Health)...
POSTED 08/22/2008 at 12:50 PM --
|
We care, therefore we are: anesthesia-related morbidity and mortality: the 46th rovenstine lecture.
Anesthesiologists keep patients alive while surgeons do things that would otherwise kill them. Anesthesiologists need to make that known as they address concerns about anesthesia-related neonatal neuronal apoptosis, postoperative cognitive dysfunction, and exacerbation of Alzheimer disease.Page: 377DOI: 10.1097/ALN.0b013e31818344daAuthors: Cottrell, James Edward M.D. * (Source: Anesthesiology)...
POSTED 08/22/2008 at 02:06 AM --
|
Mit zeroes in on alzheimer's structures - work could lead to new drugs for the common disease
MIT engineers report a new approach to identifying protein structures key to Alzheimer's disease, an important step toward the development of new drugs that could prevent such structures from forming. In the Aug. 22 issue of PLoS (Public Library of Science) Computational Biology, the researchers describe one such structure uncovered using a new computer-based technique. Collin M. Stultz, the leader of the work and the W.M. (Source: Alzheimer's / Dementia News From Medical News Today)...
POSTED 08/22/2008 at 02:00 AM --
|
3.4 million seniors hit medicare 'doughnut hole'
Title: 3.4 Million Seniors Hit Medicare 'Doughnut Hole'Category: Health NewsCreated: 8/22/2008 2:00:00 AMLast Editorial Review: 8/22/2008 (Source: MedicineNet Alzheimer)...
POSTED 08/22/2008 at 02:00 AM --
|
Peptides inhibiting specific cleaving activities of presenilins: wo2004026331
Expert Opinion on Therapeutic Patents , September 2008, Vol. 18, No. 9, Pages 1097-1100.
Genetic and biological studies provide evidence that the deposition of amyloid-β peptide contributes to the etiology of Alzheimer's disease (AD). Amyloid-β peptides are generated from amyloid-β precursor protein by β- and γ-secretases that are plausible ... (Source: Expert Opinion: Expert Opinion on Therapeutic Patents: Table of Contents)...
POSTED 08/22/2008 at 01:50 AM --
|
Protecting brain cells from diseases like alzheimer's using new method
New research provides evidence that one of the only naturally occurring fatty acids in the brain can help to protect brain cells from neurodegenerative diseases like Alzheimer's and Parkinson's. (Source: ScienceDaily Headlines)...
POSTED 08/22/2008 at 01:00 AM --
|
A novel presenilin 2 mutation (v393m) in early-onset dementia with profound language impairment
Background: Mutations in the Presenilin 2 gene (PSEN2) are rare causes of Alzheimer's disease (AD). Pathogenic mutations in the genes associated with autosomal dominant inherited AD have been shown to alter processing of the amyloid precursor protein (APP) resulting in a relative increase of the amount of A[beta]42 peptide.Methods and results: We present a patient with neuropathologically confirmed early-onset AD characterized by profound language impairment. The patient was heterozygous for a novel missense mutation in exon 11 of the PSEN2 gene leading to a predicted amino acid substitution from valine to methionine in position 393, a conserved residue. However, in vitro expression of PSEN2 V393M cDNA did not result in detectable increase of the secreted A[beta]42/40 peptide ratio. The mutation was not found in 384 control individuals tested.Conclusions: The possible pathogenic nature of the mutation is not clarified. We discuss the limitations of functional PSEN2 studies and the challenges associated with genetic counselling of family members at risk. (Source: European Journal of Neurology)...
POSTED 08/21/2008 at 11:00 PM --
|
Alzheimer's research earns joseph rogers lifetime achievement award at health care heroes breakfast
Joseph Rogers, president and senior scientist at Sun Health Research Institute, received the Lifetime Achievement Award at the 2008 Health Care Heroes Awards breakfast presented by the Phoenix Business Journal Thursday. (Source: bizjournals.com Health Care:Hospitals headlines)...
POSTED 08/21/2008 at 02:57 PM --
|
Alzheimer's research earns joseph rogers lifetime achievement award at health care heroes breakfast
Joseph Rogers, president and senior scientist at Sun Health Research Institute, received the Lifetime Achievement Award at the 2008 Health Care Heroes Awards breakfast presented by the Phoenix Business Journal Thursday. (Source: bizjournals.com Health Care:Industry Regulation headlines)...
POSTED 08/21/2008 at 02:57 PM --
|
Scientific revelation: age related decline is not inevitable
(NaturalNews) A Dutch woman decided to will her body to science when she was 82 years old. When she turned 111, she contacted the researchers, worried that she was too old to be of interest to them. On the contrary, they assured her, because of her age, they were especially interested in her.Over the next four years, she submitted to testing twice. The results showed her to be above average, even for people aged 60 to 80 years of age. There were essentially no signs of cognitive decline or memory loss.Gert Holstege, a neuroscientist at the University Medical Center Groningen, in The Netherlands examined her body after she died at 115 years of age. The results are reported in the August issue of the journal Neurobiology of Aging.To the surprise of the examiners, the woman's brain showed no sign of Alzheimer's. They found no signs of atherosclerosis, a narrowing of the arteries. Very few brain abnormalities were evident. almost no deposits of so-called beta-amyloid, which are characteristic in Alzheimer's brains. Other abnormalities present, including "neurofibrillary tangles," were too mild to cause significant mental impairment. In fact, the number of brain cells she retained was similar to that expected in healthy people between 60 and 80 years old.Scientists were amazed at these findings, because they showed that Alzheimer's and dementia are not inevitable as people age.On the Spanish island of Minorca, a man recently died at the age of 114. Reports speak of him riding his bicycle to tend to the family's orchards until he was 102. He is survived by a brother, who is 101, a nephew who is 85, and two daughters, aged 81 and 77. All seem to live an active health-filled lifestyle.Scientists tested the family's DNA for two markers associated with healthy bones and longevity. The markers were not found. Gil Atzmon, of the Albert Einstein College of Medicine in New York informs us that some 10 to 20 genes have been identified as related to longevity thus far.These findings lead scientists to believe that longevity may be more complicated than a single gene, or group of genes.As of yet, no particular diet or lifestyle has a proven association with longevity. Yet some clues have been uncovered that point us in the direction of factors which can contribute to a longer, healthier life.In the 1930's, Cornell University researchers found that rats fed a lower calorie diet than their litter mates lived 40 percent longer. The increased life span occurred regardless of the age of the rats at the time of their diet change.A mother's nutrition while she is pregnant and nursing can have a profound effect on her offspring's life span. Scientists at Cambridge University in England found that mice fed a high protein diet during pregnancy and a low protein diet while nursing had pups that lived fifty percent longer than those whose diets were reversed.Happily married couples tend to live longer, claims a study from the University of Chicago. Linda Waite reported that married men were found to live, on average, 10 years longer than non-married men, and married women lived about four years longer than non-married woman.A May 2, 2006 article in the American Journal of Medicine reports that walking is a factor in health and longevity. In their study, patients in their 70's who were in good health were challenged to walk a quarter mile. Those who completed the course were more likely to survive the next six years without disability. Those who walked slower were at higher risk of death and disability than the faster walkers, but still ahead of those who could not finish.As a matter of fact, additional studies show that walking or other exercise three or more times a week is a hedge against Alzheimer's.Staying mentally and physically active throughout life is the best way to keep the mind sharp.
Individuals with high mental stimulation had a reduced risk of Alzheimer's disease and other forms of dementia by nearly half by building and maintaining a reserve of stimulation. Another study showed that after five weeks of memory-based exercise, participants increased brain chemistry markers in a direction that was opposite to that seen in Alzheimer's. The change was concentrated in the hippocampus, one of the first brain regions to be affected in dementia.Currently, there are more than 80,000 Americans 100 years of age or older, according to the U.S. Census Bureau. That number is expected to rise to more than 580,000 centenarians by 2040. The hope is that these centenarians might live long, healthy, and happy lives.References:(http://www.livescience.com/health/080609-oldest-brain.html)(http://www.livescience.com/health/080508-long-life.html)(http://www.livescience.com/health/060524_longevity_research.html)(http://www.livescience.com/health/060502_walk_health.html)(http://www.livescience.com/health/060125_delay_dementia.html)About the authorMaryann Marshall is a fourth generation herbalist. She taught "Herbs and Your Health" classes for 25 years. Currently she is developing these classes into an online course. See http://www.grainofhope.com for more information.
Six years ago, her eldest son suffered a severe brain injury in an auto accident. His journey to wellness continues today. The family struggles through the government and medical labyrinth to assist his healing through prayer, nutrition, herbs, and other natural methods. Maryann is currently writing a book about the accident and its aftermath. You can read it in progress at: http://MiracleBoyArif.blogspot.com/. (Source: NaturalNews.com)...
POSTED 08/21/2008 at 02:00 AM --
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
IMPORTANT NOTICE:
The information provided on this site is intended for your general knowledge only and is not a substitute for professional
medical advice or treatment for specific medical conditions. You should not use this information to diagnose or treat a health problem or disease without consulting with a
qualified healthcare provider. Please consult your healthcare provider with any questions or concerns you may have regarding your condition.
|
|
|
|
|
|
|
|
Featured Product! |
 |
|
Total Balance
Men's Plus |
|
"The restoration and maintenance of normal organ and brain function, a strong immune system, and the balancing of hormones is the key to vibrant health and in avoiding premature-aging!" |
|
CLICK HERE
for more info... |
|
|
